• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viruses . Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts

tetano

Editor, Senior Moderator
Viruses


. 2022 Dec 8;14(12):2736.
doi: 10.3390/v14122736.
Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts


Louis Nevejan[SUP] 1 [/SUP], Sien Ombelet[SUP] 1 2 [/SUP], Lies Laenen[SUP] 1 2 [/SUP], Els Keyaerts[SUP] 2 [/SUP], Thomas Demuyser[SUP] 3 4 [/SUP], Lucie Seyler[SUP] 5 [/SUP], Oriane Soetens[SUP] 3 [/SUP], Els Van Nedervelde[SUP] 5 [/SUP], Reinout Naesens[SUP] 6 [/SUP], Dieter Geysels[SUP] 6 [/SUP], Walter Verstrepen[SUP] 6 [/SUP], Lien Cattoir[SUP] 7 [/SUP], Steven Martens[SUP] 7 [/SUP], Charlotte Michel[SUP] 8 [/SUP], Elise Mathieu[SUP] 8 [/SUP], Marijke Reynders[SUP] 9 [/SUP], Anton Evenepoel[SUP] 9 [/SUP], Jorn Hellemans[SUP] 9 [/SUP], Merijn Vanhee[SUP] 9 [/SUP], Koen Magerman[SUP] 10 [/SUP], Justine Maes[SUP] 10 [/SUP], Veerle Matheeussen[SUP] 11 [/SUP], Hélène Boogaerts[SUP] 11 [/SUP], Katrien Lagrou[SUP] 1 2 [/SUP], Lize Cuypers[SUP] 1 2 [/SUP], Emmanuel André[SUP] 1 2 [/SUP]



Affiliations

Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the general population in the context of a relatively high immunity gained through the early waves of coronavirus disease 19 (COVID-19), and vaccination campaigns. Despite this context, a significant number of patients were hospitalized, and identifying the risk factors associated with severe disease in the Omicron era is critical for targeting further preventive, and curative interventions. We retrospectively analyzed the individual medical records of 1501 SARS-CoV-2 positive hospitalized patients between 13 December 2021, and 13 February 2022, in Belgium, of which 187 (12.5%) were infected with Delta, and 1036 (69.0%) with Omicron. Unvaccinated adults showed an increased risk of moderate/severe/critical/fatal COVID-19 (crude OR 1.54; 95% CI 1.09-2.16) compared to vaccinated patients, whether infected with Omicron or Delta. In adults infected with Omicron and moderate/severe/critical/fatal COVID-19 (n = 323), immunocompromised patients showed an increased risk of in-hospital mortality related to COVID-19 (adjusted OR 2.42; 95% CI 1.39-4.22), compared to non-immunocompromised patients. The upcoming impact of the pandemic will be defined by evolving viral variants, and the immune system status of the population. The observations support that, in the context of an intrinsically less virulent variant, vaccination and underlying patient immunity remain the main drivers of severe disease.

Keywords: COVID-19; delta; hospitalization; immunocompromised host; omicron.
 
Back
Top Bottom